Future & Ongoing


In 2013 we launched an ongoing cancer registry through an Institutional Review Board approved study at MD Anderson Cancer Center. The purpose of the research is to obtain information about diagnosis, stage, treatment and survival of women with this disease.

Clinical Trial

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

This phase II trial studies the effect of AK104 (cadonilimab) in treating high grade neuroendocrine carcinoma of the cervix. AK104 (cadonilimab) is a new type of immunotherapy drug. Immunotherapy with monoclonal antibodies, such as AK104 (cadonilimab), may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Prior studies with similar immunotherapy drugs in patients with high grade neuroendocrine carcinoma at multiple sites, including cervical, have shown disease regression in some of the patients. All patients enrolled on the trial will get AK104 (cadonilimab) and no patients will get placebo. This study has 18 spots for women with any type of high grade neuroendocrine cervical cancer.

E-mail our team for more information about the trial:


IJGC Podcast

Dr. Michael Frumovitz is interviewed on the IJGC podcast in 2019.

View on Apple Podcasts

IJGC Journal April 2021 Discussion

USGO 2021 IJGC Presentation